YU59600A - Supstituisane indolalkanoidske kiseline - Google Patents

Supstituisane indolalkanoidske kiseline

Info

Publication number
YU59600A
YU59600A YU59600A YU59600A YU59600A YU 59600 A YU59600 A YU 59600A YU 59600 A YU59600 A YU 59600A YU 59600 A YU59600 A YU 59600A YU 59600 A YU59600 A YU 59600A
Authority
YU
Yugoslavia
Prior art keywords
indolealkanoic acids
substituted
substituted indolealkanoic
compounds
disclosed
Prior art date
Application number
YU59600A
Other languages
English (en)
Inventor
Michael Jones
David Gunn
John Howard Jones
Zandt Michael Van
Original Assignee
The Institute For Pharmaceutical Discovery Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Institute For Pharmaceutical Discovery Inc. filed Critical The Institute For Pharmaceutical Discovery Inc.
Publication of YU59600A publication Critical patent/YU59600A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Opisane su supstituisane indolalkanolske kiseline koje su primenljive u tretiranju hroničnih komplikacija koje nastaju usled dijabetis melitusa. Takodje su opisani farmaceutski preparati koji sadrže jedinjenja i postupke za tretmane koji koriste jedinjenja isto kao i postupci za njihove sinteze.[Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.
YU59600A 1998-03-31 1999-03-31 Supstituisane indolalkanoidske kiseline YU59600A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8014398P 1998-03-31 1998-03-31

Publications (1)

Publication Number Publication Date
YU59600A true YU59600A (sh) 2002-12-10

Family

ID=22155536

Family Applications (1)

Application Number Title Priority Date Filing Date
YU59600A YU59600A (sh) 1998-03-31 1999-03-31 Supstituisane indolalkanoidske kiseline

Country Status (29)

Country Link
US (9) US6214991B1 (sh)
EP (1) EP1066283B1 (sh)
JP (2) JP3494990B2 (sh)
KR (1) KR100584650B1 (sh)
CN (1) CN1205207C (sh)
AP (1) AP2000001929A0 (sh)
AT (1) ATE269861T1 (sh)
AU (1) AU774929B2 (sh)
BG (1) BG65446B1 (sh)
BR (1) BR9909358A (sh)
CA (1) CA2383983C (sh)
CZ (1) CZ300706B6 (sh)
DE (1) DE69918278T2 (sh)
EE (1) EE200000573A (sh)
ES (1) ES2224632T3 (sh)
HU (1) HUP0101672A3 (sh)
ID (1) ID27884A (sh)
IL (2) IL138711A0 (sh)
MX (1) MXPA02003122A (sh)
NO (1) NO20004900L (sh)
NZ (1) NZ507172A (sh)
OA (1) OA11622A (sh)
PL (1) PL201645B1 (sh)
SK (1) SK7522001A3 (sh)
TR (1) TR200002869T2 (sh)
TW (1) TWI243163B (sh)
WO (1) WO1999050268A2 (sh)
YU (1) YU59600A (sh)
ZA (1) ZA200005577B (sh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100584650B1 (ko) 1998-03-31 2006-05-30 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 인돌알칸산
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
JP2003505369A (ja) * 1999-07-15 2003-02-12 エヌピーエス アレリックス コーポレーション 偏頭痛を治療するための複素環式化合物
US6521659B2 (en) * 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
US20020012630A1 (en) * 2000-05-09 2002-01-31 James Nolan Methods for testing compounds useful in treating diabetic complications
WO2002051805A1 (de) 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Indol-derivate
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
ATE367812T1 (de) 2001-06-20 2007-08-15 Wyeth Corp Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1)
US6770655B2 (en) 2002-01-18 2004-08-03 Aryx Therapeutics 5-HT3 receptor antagonists and methods of use
CA2395871A1 (en) * 2002-07-26 2004-01-26 The Institutes For Pharmaceutical Discovery, Llc Substituted indolealkanoic acids derivatives and formulations containing same for use in treatment of diabetic complications
EP1539175A4 (en) * 2002-07-26 2007-09-26 Inst For Pharm Discovery Inc SUBSTITUTED INDOLALCANIC ACID DERIVATIVES AND FORMULATIONS CONTAINING THEREOF FOR USE IN THE TREATMENT OF DIABETIC COMPLICATIONS
CA2495943C (en) * 2002-08-29 2009-07-21 Merck & Co., Inc. Indoles having anti-diabetic activity
ES2266907T3 (es) 2002-12-10 2007-03-01 Wyeth Derivados sustituidos del acido 3-carbonil-indol-1-il-acetico como inhibidor del activador del plasminogeno-1 (pal-1).
AU2003297727A1 (en) 2002-12-10 2004-06-30 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
AU2003296324A1 (en) 2002-12-10 2004-06-30 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CA2523245C (en) * 2003-04-28 2012-03-06 Bayer Pharmaceuticals Corporation Indole acetic acid derivatives and their use as pharmaceutical agents
EP1620420A2 (en) * 2003-04-30 2006-02-01 The Institutes for Pharmaceutical Discovery, LLC Substituted carboxylic acids
JP2007501189A (ja) * 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
AU2005302475A1 (en) * 2004-10-28 2006-05-11 The Institutes For Pharmaceutical Discovery, Llc Substituted phenylalkanoic acids
BRPI0606524A2 (pt) * 2005-01-14 2009-06-30 Genelabs Tech Inc derivados de indol para o tratamento de infecções virais
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
US20080051384A1 (en) * 2006-07-14 2008-02-28 Genelabs Technologies, Inc. Antiviral agents
SI2046740T1 (sl) 2006-07-22 2012-12-31 Oxagen Limited Spojine s crth2 antagonistiäśno aktivnostjo
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
EP2250161B1 (en) 2008-01-18 2013-10-16 Atopix Therapeutics Limited Compounds having crth2 antagonist activity
JP2011509991A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
JP2011509990A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
GB2457040A (en) * 2008-01-30 2009-08-05 Oxagen Ltd 1-Acetic acid indole derivatives with PGD2 activity
CN106822080A (zh) 2009-04-29 2017-06-13 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
WO2012009553A1 (en) * 2010-07-16 2012-01-19 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
CA3025081A1 (en) 2016-06-21 2017-12-28 The Trustees Of Columbia University In The City Of New York Substituted 3,4-dihydrothieno [3,4-d]pyridazine compounds and use thereof as aldose reductase inhibitors
WO2019023648A1 (en) 2017-07-28 2019-01-31 Applied Therapeutics Inc. COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA
WO2019191410A1 (en) * 2018-03-29 2019-10-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors for the β-catenin / t-cell factor protein–protein interaction

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
DK151884C (da) * 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4442118A (en) * 1981-07-23 1984-04-10 Ayerst, Mckenna & Harrison, Inc. Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
DE3684410D1 (de) * 1985-11-07 1992-04-23 Pfizer Heterocyclische oxophthalazinylessigsaeure.
US4960785A (en) 1988-12-16 1990-10-02 Pfizer Inc. Indolinone derivatives
WO1993012786A1 (en) * 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US5064852A (en) * 1988-12-16 1991-11-12 Pfizer Inc. Indolinone derivatives
KR920700210A (ko) 1989-03-31 1992-02-19 기따미 가즈히꼬 신규 이미다졸 유도체, 그의 제법 및 그의 의약용도
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
US5304557A (en) 1989-12-15 1994-04-19 Pfizer Inc. Substituted oxoophthalazinyl acetic acids and analogs thereof
GB9011335D0 (en) * 1990-05-21 1990-07-11 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5312829A (en) * 1990-05-21 1994-05-17 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US5236945A (en) * 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
US5116753A (en) * 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
JPH0641071A (ja) * 1991-09-06 1994-02-15 Taisho Pharmaceut Co Ltd インドール酢酸エステル誘導体
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
GB9409583D0 (en) 1994-05-13 1994-07-06 Pfizer Ltd Indoles
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
TW401301B (en) 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US5700819A (en) * 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
TR199700993T1 (xx) * 1995-03-20 1998-03-21 Eli Lilly And Company 5-ikameli-3-(1,2,3,6-tetrahidropridin-4-il)- ve 3-(piperidin-4-il)-1H-indoller: yeni 5-HT1F agonistler.
JPH09165371A (ja) 1995-10-09 1997-06-24 Sankyo Co Ltd 複素環化合物を含有する医薬
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
KR100584650B1 (ko) * 1998-03-31 2006-05-30 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 인돌알칸산
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
US6521659B2 (en) * 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Also Published As

Publication number Publication date
US20040235933A1 (en) 2004-11-25
NO20004900D0 (no) 2000-09-29
MXPA02003122A (es) 2004-04-21
OA11622A (en) 2004-09-16
US20120270912A1 (en) 2012-10-25
US7659269B2 (en) 2010-02-09
ZA200005577B (en) 2002-02-11
TWI243163B (en) 2005-11-11
US6730794B2 (en) 2004-05-04
US20010016661A1 (en) 2001-08-23
CZ300706B6 (cs) 2009-07-22
US20030018053A1 (en) 2003-01-23
IL138711A0 (en) 2001-10-31
US7105514B2 (en) 2006-09-12
ATE269861T1 (de) 2004-07-15
CZ20003607A3 (cs) 2001-03-14
SK7522001A3 (en) 2002-02-05
US20070093530A1 (en) 2007-04-26
TR200002869T2 (tr) 2000-12-21
BR9909358A (pt) 2000-12-12
DE69918278D1 (de) 2004-07-29
NO20004900L (no) 2000-10-17
PL201645B1 (pl) 2009-04-30
JP2002509931A (ja) 2002-04-02
DE69918278T2 (de) 2005-07-14
AU774929B2 (en) 2004-07-15
NZ507172A (en) 2003-10-31
AP2000001929A0 (en) 2000-09-30
US20080214540A1 (en) 2008-09-04
US8163932B2 (en) 2012-04-24
EE200000573A (et) 2002-04-15
US6214991B1 (en) 2001-04-10
EP1066283A2 (en) 2001-01-10
CA2383983C (en) 2009-09-29
KR100584650B1 (ko) 2006-05-30
HUP0101672A2 (hu) 2002-04-29
US20100324039A1 (en) 2010-12-23
AU3459599A (en) 1999-10-18
EP1066283B1 (en) 2004-06-23
IL138711A (en) 2006-09-05
BG104819A (en) 2001-05-31
CA2383983A1 (en) 1999-10-07
ES2224632T3 (es) 2005-03-01
JP3494990B2 (ja) 2004-02-09
BG65446B1 (bg) 2008-08-29
HUP0101672A3 (en) 2002-05-28
JP2003155274A (ja) 2003-05-27
US7304079B2 (en) 2007-12-04
WO1999050268A2 (en) 1999-10-07
ID27884A (id) 2001-05-03
PL348244A1 (en) 2002-05-20
WO1999050268A3 (en) 1999-12-16
US6426344B2 (en) 2002-07-30
CN1205207C (zh) 2005-06-08
CN1296485A (zh) 2001-05-23
US20100137301A1 (en) 2010-06-03
KR20010042330A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
AP2000001929A0 (en) Substituted indolealkanoic acids.
AU2002350191A8 (en) Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors
YU73600A (sh) Novi nukleosidi koji imaju biciklične šećerne grupe
HK1031869A1 (en) 1-Ä(1-Substituted-4-piperidinyl)methylÜ-4-piperdine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds.
BG103268A (en) Propionic acid derivatives and their application
AP2001002377A0 (en) Substituted phenoxyacetic acids.
WO2001010894A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
WO2000066528A3 (en) Quinones for treatment of diseases
MXPA03001463A (es) Derivados de benzofurano o benzotiofeno de aminoalquilbenzoil, metodo para preparar los mismos y composiciones que los contienen.
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
WO2002016340A8 (fr) Aminoalkoxybenzoyl-benzofuranes ou benzothiophenes, leur procede de preparation et les compositions les contenant
HUP9601321A3 (en) Substituted (benzyloxy)-carbonyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them their use as pharmaceutical compositions or diagnostica, and the use of the said compds.
WO2003020963A3 (en) Proteins in type 2 diabetes
EP1132383A4 (en) NEW AGAROFURAN DERIVATIVES, THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE AS MEDICINE
MY138338A (en) Substituted indolealkanoic acids
YU46302A (sh) Supstituisani piroli
WO1999048851A3 (en) Processes for preparing intermediates
EP0386920A3 (en) 2-hydroxy-3-thienyloxypropylamino derivatives
BG107553A (en) Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, methods for preparing same and compositions containing same
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
AU3744100A (en) Bicyclo(3.3.1)nonenes useful for the treatment of diabetes
WO1999040078A3 (en) Process for the preparation of sotolon
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.
AU5618699A (en) N-substituted azabicycloheptane derivatives, production and use thereof
AU2003298203A1 (en) Medicaments containing substituted 2,5-diaminomethyl-1h-pyrroles